Arbutus and Genevant file 5 international patent lawsuits against Moderna; terminate sublicense for breach

Arbutus Biopharma Corp

Agreement entitles Arbutus to damages specifically allocated to Moderna's mRESVIA in pending U.S. litigation; if no allocation, parties discuss in good faith.
Arbutus terminated 2016 sublicense with ModernaTX for material breach over unpaid milestone/royalty payments; 60-day cure period.
Five lawsuits filed in Canada, Japan, Switzerland, and two UPC actions covering 30 countries, seeking injunctions and monetary relief against Spikevax and mRESVIA.
U.S. jury trial against Moderna in Delaware currently scheduled for September 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.